Elicera Therapeutics AB
F:8E8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Elicera Therapeutics AB
F:8E8
|
SE |
|
N
|
National Fuel Gas Co
SWB:NFG
|
US |
|
S
|
SanDisk Corp
XHAN:BW9
|
US |
|
Cerillion PLC
F:1VW
|
UK |
|
Picpay Holdings Netherlands BV
NASDAQ:PICS
|
BR |
|
C
|
Cuscal Ltd
ASX:CCL
|
AU |
Elicera Therapeutics AB
Elicera Therapeutics AB is a Swedish biotech company that develops cancer treatments based on the body’s immune system. Its work centers on two main drug types: oncolytic virus therapies that are meant to attack tumors and help trigger an immune response, and CAR T-cell therapies that engineer immune cells to recognize cancer more effectively. The company sells no commercial drugs yet; instead, it is built around research, clinical development, and licensing or partnering its technology. Its main customers are not patients directly but future partners such as larger pharmaceutical companies, as well as the healthcare system that would eventually use any approved medicines. Elicera makes money, if its programs succeed, through drug development partnerships, milestone payments, royalties, and eventually sales of approved therapies. What makes Elicera’s business model different is that it sits at the very early end of the cancer drug value chain, where the main product is intellectual property and clinical data rather than a marketed medicine. It is trying to build treatments that can work with the immune system itself, which gives it a more focused role than a broad drugmaker and makes its value depend heavily on the success of a small number of science-driven programs.
Elicera Therapeutics AB is a Swedish biotech company that develops cancer treatments based on the body’s immune system. Its work centers on two main drug types: oncolytic virus therapies that are meant to attack tumors and help trigger an immune response, and CAR T-cell therapies that engineer immune cells to recognize cancer more effectively.
The company sells no commercial drugs yet; instead, it is built around research, clinical development, and licensing or partnering its technology. Its main customers are not patients directly but future partners such as larger pharmaceutical companies, as well as the healthcare system that would eventually use any approved medicines. Elicera makes money, if its programs succeed, through drug development partnerships, milestone payments, royalties, and eventually sales of approved therapies.
What makes Elicera’s business model different is that it sits at the very early end of the cancer drug value chain, where the main product is intellectual property and clinical data rather than a marketed medicine. It is trying to build treatments that can work with the immune system itself, which gives it a more focused role than a broad drugmaker and makes its value depend heavily on the success of a small number of science-driven programs.
